U.S. Markets close in 3 hrs 26 mins

Insmed Incorporated (INSM)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.495-0.26 (-1.49%)
As of 12:32PM EDT. Market open.
People also watch
GNVCCRISIMMUBCRXIMGN

Insmed Incorporated

Building 10
10 Finderne Avenue
Bridgewater, NJ 08807
United States
908-977-9900
http://www.insmed.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees161

Key Executives

NameTitlePayExercisedAge
Mr. William H. LewisChief Exec. Officer, Pres and Director887.95kN/A48
Ms. Christine A. PellizzariGen. Counsel and Corp. Sec.572.26kN/A49
Ms. S. Nicole SchaefferSr. VP of HR & Corp. Services459.25k343.21k49
Dr. Eugene J. Sullivan M.D., FCCPChief Product Strategy Officer593.08kN/A52
Mr. Andrew T. DrechslerAdvisor538.76k395.42k45
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporated’s ISS Governance QualityScore as of June 2, 2017 is 7. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.